S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
BREAKING: Tiny biotech successfully treats blindness (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
15 A.I. Trading Opportunities a Day (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
15 A.I. Trading Opportunities a Day (Ad)
Vatican singles out bishops in urging reflective not reactive social media use
Sleepless in Kyiv: Nighttime Russian air campaign terrorizes citizens in Ukrainian capital
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
BREAKING: Tiny biotech successfully treats blindness (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
15 A.I. Trading Opportunities a Day (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
15 A.I. Trading Opportunities a Day (Ad)
Vatican singles out bishops in urging reflective not reactive social media use
Sleepless in Kyiv: Nighttime Russian air campaign terrorizes citizens in Ukrainian capital
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
BREAKING: Tiny biotech successfully treats blindness (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
15 A.I. Trading Opportunities a Day (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
15 A.I. Trading Opportunities a Day (Ad)
Vatican singles out bishops in urging reflective not reactive social media use
Sleepless in Kyiv: Nighttime Russian air campaign terrorizes citizens in Ukrainian capital
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
BREAKING: Tiny biotech successfully treats blindness (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
15 A.I. Trading Opportunities a Day (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
15 A.I. Trading Opportunities a Day (Ad)
Vatican singles out bishops in urging reflective not reactive social media use
Sleepless in Kyiv: Nighttime Russian air campaign terrorizes citizens in Ukrainian capital
NASDAQ:TCRT

Alaunos Therapeutics (TCRT) Earnings Date, Estimates & Call Transcripts

$0.50
-0.10 (-16.65%)
(As of 05/26/2023 04:00 PM ET)
Compare
Today's Range
$0.50
$0.57
50-Day Range
$0.46
$0.66
52-Week Range
$0.45
$4.01
Volume
2.20 million shs
Average Volume
719,426 shs
Market Capitalization
$120.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

Earnings Summary

Upcoming
Earnings Date
Aug. 21Estimated
Actual EPS
(May. 10)
-$0.04
Consensus EPS
(May. 10)
-$0.04
Last Year's Q2 EPS
(5/16/2022)
-$0.05
Skip Charts & View Estimated and Actual Earnings Data

TCRT Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

TCRT Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Alaunos Therapeutics Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20232($0.04)($0.04)($0.04)
Q2 20232($0.04)($0.04)($0.04)
Q3 20232($0.04)($0.04)($0.04)
Q4 20232($0.04)($0.04)($0.04)
FY 20238($0.16)($0.16)($0.16)
Q1 20241($0.04)($0.04)($0.04)
Q2 20241($0.04)($0.04)($0.04)
Q3 20241($0.04)($0.04)($0.04)
Q4 20241($0.04)($0.04)($0.04)
FY 20244($0.16)($0.16)($0.16)

TCRT Earnings Date and Information

Alaunos Therapeutics last issued its quarterly earnings results on May 10th, 2023. The reported ($0.04) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.04). Alaunos Therapeutics has generated ($0.17) earnings per share over the last year (($0.17) diluted earnings per share). Earnings for Alaunos Therapeutics are expected to decrease in the coming year, from ($0.16) to ($0.20) per share. Alaunos Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 21st, 2023 based off prior year's report dates.

Alaunos Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
8/21/2023
(Estimated)
        
5/10/2023Q1 2023($0.04)($0.04)($0.04)    
3/7/2023Q4 2022($0.09)($0.04)+$0.05($0.04)$0.01 million
11/14/2022Q3 2022($0.12)($0.04)+$0.08($0.04)$2.91 million
8/15/2022Q2 2022($0.11)($0.05)+$0.06($0.05)    
5/16/2022Q1 2022($0.09)($0.05)+$0.04($0.05)    
3/30/2022Q4 2021($0.09)($0.05)+$0.04($0.05)    
11/8/2021Q3 2021($0.15)($0.11)+$0.04($0.11)$0.40 million
8/13/2021Q2 2021($0.14)($0.11)+$0.03($0.11)
5/6/2021Q1 2021($0.11)($0.10)+$0.01($0.10)
2/25/2021Q4 2020($0.10)($0.11)($0.01)($0.11)
11/5/2020Q3 2020($0.09)($0.10)($0.01)($0.10)
8/6/2020Q2 2020($0.10)($0.09)+$0.01($0.09)
5/7/2020Q1 2020($0.08)($0.09)($0.01)($0.09)
3/2/2020Q4 2019($0.07)($0.09)($0.02)($0.09)
11/7/2019Q3 2019($0.09)($0.07)+$0.02$0.29
8/8/2019Q2 2019($0.09)($0.09)($0.09)
5/8/2019Q1 2019($0.09)($0.08)+$0.01($0.08)
3/5/2019Q4 2018($0.11)($0.08)+$0.03($1.45)
11/9/2018Q3 2018($0.11)($0.13)($0.02)($0.13)
8/8/2018Q2 2018($0.12)($0.12)($0.12)
5/10/2018Q1 2018($0.13)($0.15)($0.02)($0.15)$1.55 million$0.15 million
3/1/2018Q4 2017($0.13)($0.13)($0.13)$1.59 million$1.60 million
11/6/2017Q3 2017($0.13)($0.13)($0.13)$1.59 million$1.60 million
7/31/2017Q2 2017($0.13)($0.13)($0.13)$1.59 million$1.60 million
5/1/2017Q1 2017($0.12)($0.15)($0.03)($0.15)$1.59 million$1.60 million
2/16/2017Q4 2016($0.11)($0.11)($0.11)$1.62 million$1.60 million
11/9/2016Q3 2016($0.11)($0.11)($0.11)$1.82 million$1.60 million
8/9/2016Q2 2016($0.11)($0.10)+$0.01$0.81$1.75 million$1.70 million
5/10/2016Q1 2016($0.09)($0.09)($0.09)$1.97 million$1.97 million
2/24/2016Q4 2015($0.04)($0.07)($0.03)($0.07)$1.82 million$1.92 million
11/2/2015Q3 2015($0.10)($0.14)($0.04)($0.14)$1.69 million$1.87 million
8/10/2015Q2 2015($0.11)($0.11)($0.11)$57.70 million$0.27 million
5/7/2015Q1 2015($0.12)($0.10)+$0.02$0.49$0.02 million$0.27 million
2/26/2015Q4 2014($0.13)($0.09)+$0.04($0.09)$0.53 million$0.34 million
10/30/2014Q3 2014($0.12)($0.12)($0.18)$0.20 million$0.63 million
8/7/2014Q2 2014($0.11)($0.12)($0.01)($0.18)$0.20 million$0.20 million
5/8/2014Q1 2014($0.08)($0.10)($0.02)($0.10)$0.20 million$0.20 million
3/3/2014Q4 2013($0.14)($0.07)+$0.07($0.05)$0.20 million$0.20 million
10/22/2013Q3 2013($0.17)($0.11)+$0.06($0.02)$0.20 million$0.20 million
8/8/2013Q2 2013($0.22)($0.22)($0.22)$0.20 million$0.20 million
5/7/2013Q1 2013($0.28)($0.28)($0.41)$0.20 million$0.20 million












Alaunos Therapeutics Earnings - Frequently Asked Questions

When is Alaunos Therapeutics's earnings date?

Alaunos Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 21st, 2023 based off last year's report dates. Learn more on TCRT's earnings history.

Did Alaunos Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Alaunos Therapeutics (NASDAQ:TCRT) reported ($0.04) earnings per share (EPS) to hit the analysts' consensus estimate of ($0.04). Learn more on analysts' earnings estimate vs. TCRT's actual earnings.

How can I listen to Alaunos Therapeutics's earnings conference call?

The conference call for Alaunos Therapeutics's latest earnings report can be listened to online. Listen to Conference Call

How can I read Alaunos Therapeutics's conference call transcript?

The conference call transcript for Alaunos Therapeutics's latest earnings report can be read online. Read Transcript

How much revenue does Alaunos Therapeutics generate each year?

Alaunos Therapeutics (NASDAQ:TCRT) has a recorded annual revenue of $2.92 million.

How much profit does Alaunos Therapeutics generate each year?

Alaunos Therapeutics (NASDAQ:TCRT) has a recorded net income of -$37.73 million. TCRT has generated -$0.17 earnings per share over the last four quarters.

What is Alaunos Therapeutics's EPS forecast for next year?

Alaunos Therapeutics's earnings are expected to decrease from ($0.16) per share to ($0.20) per share in the next year.

More Earnings Resources from MarketBeat

This page (NASDAQ:TCRT) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -